Biognosys Announces New Release of Spectronaut™
15.6.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for life sciences research and development, announced today the launch of Spectronaut 15. The software provides fast, robust, and seamless data analysis for mass spectrometry (MS) based data-independent acquisition (DIA) proteomics. Thus, Spectronaut enables the investigation of protein expression, function, and structure across all major biological species and sample types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005013/en/
Spectronaut - The gold standard for DIA proteomics analysis (Graphic: Business Wire)
Spectronaut is a commercial software for industry and academia and is also used as part of Biognosys' discovery proteomics contract research services. In conjunction with the company's proprietary, patented Hyper Reaction Monitoring (HRM™) technology, Spectronaut enables reproducible and precise quantification of up to 10,000 proteins in large-scale studies. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for R&D and clinical research.
Since its first release in 2003, Spectronaut is continuously improving and always supports the newest technologies in data acquisition. The 15th generation of the software comes with an array of novel features and updates, such as:
- Significant improvements to directDIA, the industry-leading library-free DIA workflow
- A more comprehensive toolset for post-translational modification (PTM) analysis
- Improved deep learning augmentation for immunopeptidomics and ion mobility data analysis
- Powerful data visualization in an intuitive user interface
"With this new Spectronaut release, we offer our software users and service customers once more a higher level of performance, user experience, and insights to support their discovery proteomics research", said Biognosys CTO Lukas Reiter, PhD.
Spectronaut lead developer Oliver M. Bernhardt will share more details on the new features during the Spectronaut 15 launch webinar , Expand Biological insights with DIA Proteomics , held today at 5 PM CEST. Beyond that, Guest speaker Andreas-David Brunner will present a robust and scalable single-cell DIA proteomics workflow using ion mobility technology (dia-PASEF), developed at the Max Planck Institute of Biochemistry (Matthias Mann Lab).
Spectronaut 15 is fully vendor-independent and compatible with proteomics data acquired on instruments of all major mass spectrometer vendors.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
"Spectronaut has made it possible to implement our breakthrough dia-PASEF technology in many of our customer's facilities. With the latest Spectronaut release, the support for our ion mobility technology has seen a significant improvement, and we are looking forward to continuing our collaboration with Biognosys to maintain Spectronaut as a key solution for Bruker's DIA workflows."
Andreas Huhmer, Director Marketing, Mass Spectrometry Solutions at Thermo Fisher Scientific:
"Biognosys' Spectronaut is our software of choice to analyze DIA data in internal projects, including acquisition method development. Of course, it is also the solution we strongly recommend to our customers. Spectronaut has always been at the forefront when it comes to supporting our technology, and its ease of use and versatility makes it the best partner for DIA data analysis."
For more information about Spectronaut, including details about free trials and pricing, please visit biognosys.com/spectronaut.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys' unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at www.biognosys.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005013/en/
Contact information
Lukas Reiter, PhD
Chief Technology Officer
Phone +41 (0) 44 738 20 40
lukas.reiter@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom